Quantitative assessment of the diagnostic role of human telomerase activity from pancreatic juice in pancreatic cancer

Tumor Biology

Volumn 35, Issue 8, 2014, Pages 7897-7904

  Wang, Siliang ^a   Chen, Xiaodong ^a   Tang, Meiyue ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Diagnosis; Meta analysis; Pancreatic cancer; Pancreatic juice; Telomerase

Indexed keywords

TELOMERASE;

ENZYMOLOGY; HUMAN; META ANALYSIS; METABOLISM; PANCREAS JUICE; PANCREATIC NEOPLASMS; PUBLISHING;

HUMANS; PANCREATIC JUICE; PANCREATIC NEOPLASMS; PUBLICATION BIAS; TELOMERASE;

EID: 84922391863     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2053-3     Document Type: Article

References (31)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.
2. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363:1049–57.
3. Real FX. A catastrophic hypothesis for pancreas cancer progression. Gastroenterology. 2003;124:1958–64.
4. Bansal P, Sonnenberg A. Pancreatitis is a risk factor for pancreatic cancer. Gastroenterology. 1995;109:247–51.
5. American Cancer Society. Cancer Facts & Figures. 2010http://www.cancer.org/acs/groups/content/@nho/documents/document/acspc-024113.
6. Tanase CP, Neagu M, Albulescu R, et al. Advances in pancreatic cancer detection. Adv Clin Chem. 2010;51:145–80.
7. Ni X, Bai X, Mao Y, et al. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol. 2005;31:164–9.
8. Simeone DM, Ji B, Banerjee M, et al. CEACAM1, a novel serum biomarker for pancreatic cancer. Pancreas. 2007;34:436–43.
9. Cwik G, Wallner G, Skoczylas T, Ciechanski A, Zinkiewicz K. Cancer antigens 19–9 and 125 in the differential diagnosis of pancreatic mass lesions. Arch Surg. 2006;141:968–73.
10. Liao Q, Zhao YP, Yang YC, Li LJ, Long X, Han SM. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head. Hepatobiliary Pancreat Dis Int. 2007;6:641–5.
11. Marchese R, Muleti A, Pasqualetti P, et al. Low correspondence between K-ras mutations in pancreatic cancer tissue and detection of K-ras mutations in circulating DNA. Pancreas. 2006;32:171–7.
12. Schmiegel WH, Kreiker C, Eberl W, et al. Monoclonal antibody defines CA 19–9 in pancreatic juices and sera. Gut. 1985;26:456–60.
13. Counter CM, Avilion AA, LeFeuvre CE, Harley CB, West MD, Ho PL, et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J. 1992;11:1921–9.
14. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011–5.
15. Hiyama K, Hiyama E, Ishioka S, Yamakido M, Inai K, Gazdar AF, et al. Telomerase activity in small-cell and non-small-cell lung cancers. J Natl Cancer Inst. 1995;87:895–902.
16. Suehara N, Mizumoto K, Muta T, Tominaga Y, Shimura H, Kitajima S, et al. Telomerase elevation in pancreatic ductal carcinoma compared to non-malignant pathological states. Clin Cancer Res. 1997;3:993–8.
17. Whiting PF, Weswood ME, Rutjes AW, et al. Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol. 2003;3:25.
18. Devillé WL, Buntinx F, Bouter LM, et al. Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol. 2002;2:9.
19. Vamvakas EC. Meta-analyses of studies of the diagnostic accuracy of laboratory tests: a review of the concepts and methods. Arch Pathol Lab Med. 1998;122:675–86.
20. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000;53:1119–29.
21. Iwao T, Hyama E, Yokoyama T, et al. Telomerase activity for the preoperative diagnosis of pancreatic cancer. J Natl Cancer Inst. 1997;89(21):1621–3.
22. Uehara H, Nakaizumi A, Tatsuta M, et al. Diagnosis of pancreatic cancer by detecting telomerase activity in pancreatic juice: comparison with K-ras mutation. Am J Gastroenterol. 1999;94(9):2513–8.
23. Myung SJ, Kim MH, Kim YS, et al. Telomerase activity in pure pancreatic juice for the diagnosis of pancreatic cancer may be complementary to K-ras mutation. Gastrointest Endosc. 2000;51(6):708–13.
24. Seki K, Suda T, Aoyagi Y, et al. Diagnosis of pancreatic adenocarcinoma by detection of human telomerase reverse transcriptase messenger RNA in pancreatic juice with sample qualification. Clin Cancer Res. 2001;7(7):1976–81.
25. Gong XM, Chen YF, Chen YJ, et al. Telomerase activity in pancreatic carcinoma specimen and pancreatic juice cell. Chin J Gastroenterol Hepatol. 2002;11(1):50–3.
26. Mizumoto K, Tanaka M. Genetic diagnosis of pancreatic cancer. J Hepatobiliary Pancreat Surg. 2002;9(1):39–44.
27. Ye YH, Hao JH, Yang CM. Role of determination of telomerase activity in pancreatic juice in the differential diagnosis of pancreatic diseases. China J Cancer Prev Treat. 2003;10(4):383–5.
28. Liu T, Wang CY, Wan CD, et al. Detection of the expression of hTERT mRNA and telomerase activity of pancreatic juice in the diagnosis of pancreatic cancer. Chin J Gen Surg. 2004;13(7):527–30.
29. Xu LH, Lu HS, Ji YL, et al. Diagnostic value of pancreatic cancer by detecting telomerase and K-ras gene in pancreatic juice. J Clin Intern Med. 2007;24(12):836–7.
30. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003;56:1129–35.
31. Jones CM, Athanasiou T. Summary receiver operating characteristic curve analysis techniques in the evaluation of diagnostic tests. Ann Thorac Surg. 2005;79:16–20.